another AASLD guideline update is likely to follow.
A major concern for payers continues to be
“warehousing” or the intentional delay of treatment
in anticipation of the next generation of options.
The volume of patients being “warehoused” in
anticipation of all oral interferon-free regimens is
unknown. The financial impact of an abrupt surge in
HCV treatment utilization and the ability to prepare for
exponential growth in HCV membership will be vitally
important for all payers in 2014 and beyond.
The current market for